---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-037042"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2021-07-19T23:59:59+00:00"
generated_at: "2026-06-30T04:31:48.400860+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arcus CMO Bill Grossman moves to Gilead; Kartik Krishnan takes over clinical development

## Summary
- Bill Grossman, MD, PhD, resigns as CMO effective July 26, 2021, to become SVP of Oncology Clinical Research at Gilead.
- Grossman will be Arcus's point of contact at Gilead for co-development activities under the alliance.
- Kartik Krishnan, MD, PhD, promoted to lead Arcus clinical development, effective July 26.
- Grossman will provide consulting to Arcus for up to 3 months; his stock option exercise period extended to July 1, 2022.
- Krishnan joined Arcus in 2019 and has been assuming increasing responsibilities since December 2020.

## SEC filing metadata
- accession: 0001564590-21-037042
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2021-07-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/0001564590-21-037042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/rcus-8k_20210716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-037042
- JSON: https://secwatch.observer/filing/0001564590-21-037042.json
- Plain text: https://secwatch.observer/filing/0001564590-21-037042.txt

## Key facts
- Executive change
  Bill Grossman resigned as Chief Medical Officer at Arcus Biosciences, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On July 16, 2021, Bill Grossman, MD, Arcus Biosciences, Inc.’s Chief Medical Officer, resigned from Arcus to become SVP of Oncology Clinical Research at Gilead Sciences, Inc., effective July 26, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000156459021037042/0001564590-21-037042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.